Resolution Health

NQF Measures

On January 4, 2010 Resolution Health, Inc.,(RHI) an industry-leading personal health care guidance company and subsidiary of WellPoint, Inc, received endorsement for 25 measures developed by the company. A total of 70 measures were endorsed by the National Quality Forum (NQF) that encourage the use of electronic data to measure, report and improve the delivery of health care across the U.S.


NQF Measures Request Form

To request information about our NQF-endorsed measures, please complete the following form:

First Name *
Last Name *
 
Title
Position
Company *
Department
Address 1 *
Address 2
City *
State *
ZIP *
 
 
 
Phone
Email *
 
* Required
Optional: How would you describe yourself?
Practicing physician
Health plan member
Health plan representative
NQF representative
Other

Select the NQF-endorsed measures you would like to request:


NQF # Measure Name Measure Short Description
0578 Ambulatory initiated Amiodarone Therapy: TSH Test This measure identifies the percentage of patients who had a TSH baseline measurement at the start of amiodarone therapy
0579 Annual Cervical Cancer Screening for High-Risk Patients This measure identifies women age 12 to 65 diagnosed with cervical dysplasia (CIN 2), cervical carcinoma-in-situ, or HIV/AIDS prior to the measurement year, and who still have a cervix, who had a cervical CA screen during the measurement year.
0580 Bipolar antimanic agent This measure identifies the percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.
0581 Deep Vein Thrombosis Anticoagulation >= 3 Months This measure identifies patients with deep vein thrombosis (DVT) on anticoagulation for at least 3 months after the diagnosis
0582 Diabetes and Pregnancy: Avoidance of Oral Hypoglycemic Agents This measure identifies pregnant women with diabetes who are not taking an oral hypoglycemic agent.
0583 Dyslipidemia new med 12-week lipid test This measure identifies patients age 18 or older who started lipid-lowering medication during the measurement year and had a lipid panel checked within 3 months after starting drug therapy.
0584 Hepatitis C: Viral Load Test This measure identifies the percentage of patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing prior to initiation of antiviral therapy.
0585 Hydroxychloroquine annual eye exam This measure identifies the percentage of patients with Rheumatoid Arthritis who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year.
0586 Warfarin PT/INR Test This measure identifies the percentage of patients taking warfarin during the measurement year who had at least one PT/INR test within 30 days after the first warfarin prescription in the measurement year
0587 Tympanostomy Tube Hearing Test This measure identifies the percentage of patients age 2 through 12 years with OME who received tympanostomy tube(s) insertion during the measurement year and had a hearing test performed within 6 months prior to the initial tube placement.
0588 Stent drug-eluting antiplatelet This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a drug-eluting intracoronary stent during the first 9 months of the measurement year, who had consistent use of an antiplatelet medication for 12 months following stent placement.
0589 Rheumatoid Arthritis New DMARD Baseline Serum Creatinine This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline serum creatinine testing within 90 days before to 14 days after the new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year.
0590 Rheumatoid Arthritis New DMARD Baseline Liver Function Test This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline liver function testing (AST or ALT) within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.
0591 Rheumatoid Arthritis New DMARD Baseline CBC This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline complete blood count (CBC) testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year.
0592 Rheumatoid Arthritis Annual ESR or CRP This measure identifies adult patients with a history of rheumatoid arthritis who have received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests during the measurement year.
0593 Pulmonary Embolism Anticoagulation >= 3 Months This measure identifies patients with pulmonary embolism (PE) on anticoagulation for at least 3 months after the diagnosis.
0594 Post MI: ACE inhibitor or ARB therapy This measure identifies patients with ST elevation MI (STEMI), or non-ST elevation MI (NSTEMI) plus a history of hypertension, heart failure and/or diabetes prior to the measurement year who are taking an ACEI or an ARB during the measurement year.
0595 Lithium Annual Lithium Test in ambulatory setting This measure identifies the percentage of patients taking lithium who have had at least one lithium level test after the earliest observed lithium prescription during the measurement year.
0596 Lithium Annual Thyroid Test in ambulatory setting This measure identifies the percentage of patients taking lithium who have had at least one thyroid function test after the earliest observed lithium prescription during the measurement year.
0597 Methotrexate: LFT within 12 weeks This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a liver function test (LFT) in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.
0598 Methotrexate: CBC within 12 weeks This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim
0599 Methotrexate: Creatinine within 12 weeks This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim.
0600 New Atrial Fibrillation: Thyroid Function Test This measure identifies patients with new-onset atrial fibrillation during the measurement year who have had a thyroid function test 6 weeks before or after the diagnosis of atrial fibrillation.
0601 New Rheumatoid Arthritis Baseline ESR or CRP within Three Months This measure identifies adult patients newly diagnosed with rheumatoid arthritis during the first 8 months of the measurement year who received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests either 4 months (3 months + 1-month grace period) before or after the initial diagnosis.
0609 Lithium Annual Creatinine Test in ambulatory setting This measure identifies the percentage of patients taking lithium who have had at least one creatinine test after the earliest observed lithium prescription during the measurement year.
If you have any questions, please contact us at NQFMeasures@resolutionhealth.com